15 research outputs found
Definicijos
Versta iš: Definitiones [Sp.], in: Platonis opera, ed. J. Burnet, Vol. 5, Oxford: Clarendon Press, 1907. St III. 411a–416a.Iš sen. graikų kalbos vertė filosofinio teksto vertimo seminaro dalyviai:Vytautas Ališauskas, Vilius Bartninkas, Žygintas Beručka, Paulius Garbačiauskas, Vilius Kubekas, Aistė Noreikaitė, Virgilijus Petuška, Gendvilė Svirskaitė, Gintarė Vaičiulytė, Raminta VažgėlaitėParengė Paulius Garbačiauskas
The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE
Aim To estimate the cost-effectiveness of the EmERGE
Pathway of Care for medically stable people living with HIV
(PLHIV) at the University Hospital for Infectious Diseases
(UHID), Zagreb. The Pathway includes a mobile application
enabling individuals to communicate with their caregivers.
Methods This study involving 293 participants collected
data on the use of HIV outpatient services one year before
and after EmERGE implementation. In departments sup
-
porting HIV outpatients, a micro-costing exercise was per
-
formed to calculate unit costs. These were combined with
mean use of HIV services per patient year (MPPY) to esti
-
mate average annual costs. Primary outcomes were CD4
count, viral load, and secondary outcomes were patient
activation, PAM13; and quality of life, PROQOL-HIV. Infor
-
mation on out-of-pocket expenditures was also collected.
Results Outpatient visits decreased by 17%, from 4.0 (95%
CI 3.8-4.3) to 3.3 MPPY (95% CI 3.1-3.5). Tests, including CD4
count, decreased, all contributing to a 33% reduction of
annual costs: 7139 HRK (95% CI 6766-7528) to 4781 HRK
(95% CI 4504-5072). Annual costs including anti-retroviral
drugs (ARVs) decreased by 5%: 43 101 HRK (95% CI 42 728-
43,490) to 40 743 HRK (95% CI 40 466-41,034). ARVs remain
the main cost driver in stable PLHIV. Primary and secondary
outcomes did not change substantially between periods.
Conclusion EmERGE Pathway was a cost-saving interven
-
tion associated with changes in management, and a reduc
-
tion in outpatient visits, tests, and costs. ARV costs domi
-
nated costs. Future efficiencies are possible if EmERGE is
introduced to other PLHIV across the UHID and if ARV pric
-
es are reduced
Ethical Meaning of Metaphysics and Communication Otherwise: E. Levinas
Straipsnyje svarstoma Emmanuelio Levino kritika Vakarų metafizikos atžvilgiu, kuri, turint omenyje Martiną Heideggerį, gali būti įvardyta užmarštimi. Tačiau šiuo atveju tai ne būties, o kitaip nei būties (autrement q’etre) užmarštis. Aptariant kitybės sampratą ir pabrėžiant skirtumo aspektą, parodoma, kad kitybė Levino filosofijoje sutinkama ne konceptualiai, ne savirefleksijos būdu ar ontologiškai, o per išraišką, per Kito veidą. Drauge tai yra ir komunikacijos su Kitu užmezgimas. Analizuojant susitikimo su Kitu ir komunikacijos su juo pobūdį, svarstoma, kaip Levinui pavyksta išvengti ontologinio ir pažintinio santykio bei grįžti prie tradicijos užmirštos etinės metafizikos dimensijos
The case for investing in public health: a public health summary report for EPHO 8
The economic crisis has led to increased demand and reduced resources for health sectors. The trend for increasing healthcare costs to individuals, the health sector and wider society is significant. Public health can be part of the solution to this challenge. The evidence shows that prevention can be cost-effective, provide value for money and give returns on investment in both the short and longer terms. This public health summary outlines quick returns on investment for health and other sectors for interventions that promote physical activity and healthy employment; address housing and mental health; and reduce road traffic injuries and violence. Vaccinations and screening programmes are largely cost-effective. Population-level approaches are estimated to cost on average five times less than individual interventions. This report gives examples of interventions with early returns on investment and approaches with longer-term gains. Investing in cost-effective interventions to reduce costs to the health sector and other sectors can help create sustainable health systems and economies for the future
Recommended from our members
The efficiency of the EmERGE pathway to provide continuity of care for medically stable people living with HIV in Belgium
No description supplie
Monitoring autophagy immunohistochemically and ultrastructurally during human head and neck carcinogenesis. Relationship with the DNA damage response pathway
Autophagy is a catabolic process that preserves cellular homeostasis. Its exact role during carcinogenesis is not completely defined. Specifically in head and neck cancer, such information from clinical settings that comprise the whole spectrum of human carcinogenesis is very limited. Towards this direction, we examined the in situ status of the autophagy-related factors, Beclin-1, microtubule-associated protein 1 light chain 3, member B (LC3B) and sequestosome 1/p62 (p62) in clinical material covering all histopathological stages of human head and neck carcinogenesis. This material is unique as each panel of lesions is derived from the same patient and moreover we have previously assessed it for the DNA damage response (DDR) activation status. Since Beclin-1, LC3B and p62 reflect the nucleation, elongation and degradation stages of autophagy, respectively, their combined immunohistochemical (IHC) expression profiles could grossly mirror the autophagic flux. This experimental approach was further corroborated by ultrastructural analysis, applying transmission electron microscopy (TEM). The observed Beclin-1/LC3B/p62 IHC patterns, obtained from serial sections analysis, along with TEM findings are suggestive of a declined authophagic activity in preneoplastic lesions that was restored in full blown cancers. Correlating these findings with DDR status in the same pathological stages are indicative of: (i) an antitumor function of autophagy in support to that of DDR, possibly through energy deprivation in preneoplastic stages, thus preventing incipient cancer cells from evolving; and (ii) a tumor-supporting role in the cancerous stage